Total Payments
$6,197
2024 Payments
$490.29
Companies
18
Transactions
435
Medicare Patients
1,794
Medicare Billing
$167,827
Payment Breakdown by Category
Food & Beverage$6,135 (99.0%)
Education$62.35 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,135 | 428 | 99.0% |
| Education | $62.35 | 7 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amarin Pharma Inc. | $2,948 | 208 | $0 (2022) |
| PFIZER INC. | $1,408 | 110 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $625.27 | 22 | $0 (2024) |
| ABBVIE INC. | $404.50 | 41 | $0 (2024) |
| Novo Nordisk Inc | $171.35 | 10 | $0 (2023) |
| GlaxoSmithKline, LLC. | $155.57 | 10 | $0 (2024) |
| Lilly USA, LLC | $105.60 | 6 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $64.58 | 5 | $0 (2019) |
| Allergan, Inc. | $59.16 | 5 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $57.02 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $490.29 | 14 | AstraZeneca Pharmaceuticals LP ($387.95) |
| 2023 | $297.10 | 15 | AstraZeneca Pharmaceuticals LP ($130.71) |
| 2022 | $412.71 | 32 | Amarin Pharma Inc. ($175.43) |
| 2021 | $1,437 | 98 | Amarin Pharma Inc. ($947.20) |
| 2020 | $1,102 | 63 | Amarin Pharma Inc. ($794.64) |
| 2019 | $625.63 | 64 | PFIZER INC. ($290.16) |
| 2018 | $847.97 | 82 | PFIZER INC. ($329.20) |
| 2017 | $983.80 | 67 | Amarin Pharma Inc. ($507.15) |
All Payment Transactions
435 individual payment records from CMS Open Payments — Page 2 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/22/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: RESPIRATORY | ||||||
| 03/21/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/14/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.98 | General |
| Category: NEUROSCIENCE | ||||||
| 01/31/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/05/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: RESPIRATORY | ||||||
| 12/01/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/29/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $11.68 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.11 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.76 | General |
| Category: NEUROSCIENCE | ||||||
| 09/01/2022 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: Cardiovascular | ||||||
| 08/05/2022 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Cardiovascular | ||||||
| 07/05/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: NEUROSCIENCE | ||||||
| 06/30/2022 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: Cardiovascular | ||||||
| 06/22/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.74 | General |
| Category: NEUROSCIENCE | ||||||
| 05/31/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: RESPIRATORY | ||||||
| 05/12/2022 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: Cardiovascular | ||||||
| 05/12/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.21 | General |
| Category: NEUROSCIENCE | ||||||
| 04/26/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.34 | General |
| Category: NEUROSCIENCE | ||||||
| 04/13/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2022 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $9.98 | General |
| Category: Cardiovascular | ||||||
| 04/08/2022 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: Cardiovascular | ||||||
| 04/08/2022 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: Diabetes | ||||||
| 03/29/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.93 | General |
| Category: NEUROSCIENCE | ||||||
| 03/15/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/08/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.87 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 381 | 697 | $78,335 | $39,515 |
| 2022 | 11 | 438 | 816 | $82,560 | $42,108 |
| 2021 | 13 | 473 | 918 | $85,893 | $44,388 |
| 2020 | 14 | 502 | 915 | $90,951 | $41,816 |
Total Patients
1,794
Total Services
3,346
Medicare Billing
$167,827
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 123 | 396 | $43,200 | $24,337 | 56.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 67 | 67 | $16,025 | $8,748 | 54.6% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 17 | 17 | $5,200 | $2,846 | 54.7% |
| 36410 | Insertion of needle into vein (3 years or older) | Office | 2023 | 61 | 86 | $2,250 | $1,067 | 47.4% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 56 | 56 | $6,150 | $1,044 | 17.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 17 | 17 | $2,725 | $967.63 | 35.5% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2023 | 14 | 14 | $1,750 | $363.02 | 20.7% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 26 | 44 | $1,035 | $141.24 | 13.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 138 | 450 | $49,330 | $27,524 | 55.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 52 | 52 | $12,400 | $6,908 | 55.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 26 | 26 | $4,075 | $1,545 | 37.9% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 21 | 29 | $2,555 | $1,472 | 57.6% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2022 | 21 | 29 | $3,125 | $1,472 | 47.1% |
| 36410 | Insertion of needle into vein (3 years or older) | Office | 2022 | 68 | 98 | $2,590 | $1,134 | 43.8% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 44 | 44 | $5,475 | $838.91 | 15.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 19 | 20 | $770.00 | $608.48 | 79.0% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 21 | 22 | $1,150 | $461.74 | 40.2% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 15 | 33 | $825.00 | $106.73 | 12.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 13 | 13 | $265.00 | $38.67 | 14.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 143 | 489 | $53,675 | $30,306 | 56.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 39 | 39 | $9,375 | $5,348 | 57.0% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2021 | 21 | 41 | $4,275 | $2,104 | 49.2% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 20 | 40 | $3,460 | $2,052 | 59.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 21 | 21 | $3,325 | $1,520 | 45.7% |
| 36410 | Insertion of needle into vein, patient 3 years or older | Office | 2021 | 64 | 88 | $2,260 | $1,102 | 48.8% |
About Dr. Salimah Cumber, M.D
Dr. Salimah Cumber, M.D is a Family Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912011966.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Salimah Cumber, M.D has received a total of $6,197 in payments from pharmaceutical and medical device companies, with $490.29 received in 2024. These payments were reported across 435 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($6,135).
As a Medicare-enrolled provider, Cumber has provided services to 1,794 Medicare beneficiaries, totaling 3,346 services with total Medicare billing of $167,827. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Houston, TX
- Active Since 08/18/2006
- Last Updated 03/26/2014
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1912011966
Products in Payments
- Vascepa (Drug) $2,948
- LYRICA (Drug) $557.76
- AIRSUPRA (Drug) $387.95
- VRAYLAR (Drug) $318.88
- EUCRISA (Drug) $272.38
- COLOGUARD (Device) $224.87
- FARXIGA (Drug) $190.54
- COLOGUARD DNA CAPTURE REAGENTS (Device) $171.38
- Tresiba (Drug) $142.34
- TRELEGY ELLIPTA (Drug) $95.01
- CHANTIX (Drug) $77.87
- TOVIAZ (Drug) $77.81
- UBRELVY (Drug) $74.00
- JANUVIA (Drug) $52.76
- MOUNJARO (Drug) $47.81
- SEEBRI (Drug) $47.71
- TRULICITY (Drug) $47.10
- XARELTO (Drug) $36.55
- Otezla (Drug) $33.81
- VIBERZI (Drug) $33.64
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Houston
Shannon Schrader, Md, MD
Family Medicine — Payments: $383,042
Family Medicine $383,042
Dr. Eric Nolen, Md, Mba, MD, MBA
Family Medicine — Payments: $158,026
Family Medicine $158,026
Candice Winful, M.d, M.D
Family Medicine — Payments: $123,290
Family Medicine $123,290
Dr. Joe Pouzar, M.d, M.D
Family Medicine — Payments: $104,957
Family Medicine $104,957
Victor Escobar, M.d, M.D
Family Medicine — Payments: $79,840
Family Medicine $79,840
Dr. Oscar De Valle, M.d, M.D
Family Medicine — Payments: $78,226
Family Medicine $78,226